Literature DB >> 6985834

Relationship of lysozyme (muramidase) to histiocytic differentiation in malignant histocytosis: an immunohistochemical study.

G Mendelsohn, J C Eggleston, R B Mann.   

Abstract

Malignant histiocytosis (MH) is a rare, usually fatal systemic disease considered to be a neoplasm of true histiocytes. Because MH may be difficult to differentiate from non-Hodgkin's lymphomas or carcinoma, we examined surgical and autopsy material from 10 patients with MH using the immunoperoxidase technique to determine if the presence of intracellular lysozyme is helpful in making this distinction. The cases of MH were divided into three groups based on the degree of cytologic atypia and the amount of phagocytic activity of the neoplastic cells: group I--minimal cytologic atypia and rare erythrophagocytosis; group II--minimal cytologic atypia with extensive erythrophagocytosis: group III--moderate to marked cytologic atypia and rare phagocytosis. Moderate to strong staining for lysozyme was observed in the neoplastic cells of group I, weak or absent staining in group II cells, and no staining in group III cells. These findings suggest the loss of detectable enzyme in poorly differentiated or dedifferentiated neoplastic histiocytes. Consideration must be given to these observations in evaluating the use of lysozyme as a possible serum or tissue aid to the diagnosis of MH.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6985834     DOI: 10.1002/1097-0142(19800115)45:2<273::aid-cncr2820450212>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Lectin I of Ulex europaeus as a marker for a subset of histiocytic tumours of the lymph node.

Authors:  L P Ruco; E Pescarmona; F Pezzella; S Uccini; A M Testi; C Cartoni; C D Baroni
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

Review 2.  The role of the spleen in leukemias and lymphomas including Hodgkin's disease.

Authors:  R Maurer
Journal:  Experientia       Date:  1985-02-15

3.  A macrophage-monocyte cell line from a dog with malignant histiocytosis.

Authors:  M L Wellman; S Krakowka; R M Jacobs; G J Kociba
Journal:  In Vitro Cell Dev Biol       Date:  1988-03

4.  PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule.

Authors:  B Falini; L Flenghi; S Pileri; M Gambacorta; B Bigerna; H Durkop; F Eitelbach; J Thiele; R Pacini; A Cavaliere
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

5.  Tumor cell line characterization of a malignant histiocytosis transplanted into nude mice.

Authors:  M F Rousseau-Merck; F Jaubert; M A Bach; P Niaudet; D Cottreau; C Nezelof
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

6.  Malignant lymphoma of true histiocytic origin: histiocytic sarcoma. A morphological, ultrastructural, immunological, cytochemical and clinical study of 10 cases.

Authors:  P van der Valk; J te Velde; J Jansen; D J Ruiter; P J Spaander; C J Cornelisse; C J Meijer
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

7.  EBM/11 reactivity in malignant histiocytosis.

Authors:  P M Kelly; M McGovern; K C Gatter; J M Theaker; J O McGee
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

8.  Immunohistochemical differentiation between histiocytic and lymphoid neoplasms.

Authors:  P G Isaacson; D B Jones
Journal:  Histochem J       Date:  1983-07

9.  Atypical lymphohistiocytic bone tumour (osseous variant of Rosai-Dorfman disease?).

Authors:  J Hamels; L Fiasse; J Thiery
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.